Clene Inc. Expected to Earn Q1 2024 Earnings of ($0.09) Per Share (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNNFree Report) – Stock analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Clene in a report released on Wednesday, March 13th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.09) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Clene’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Clene’s Q2 2024 earnings at ($0.09) EPS, Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.36) EPS, FY2025 earnings at ($0.36) EPS, FY2026 earnings at ($0.31) EPS and FY2027 earnings at $0.00 EPS.

Clene Stock Performance

Shares of CLNN opened at $0.40 on Monday. The company has a 50-day simple moving average of $0.45 and a 200-day simple moving average of $0.46. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $51.51 million, a PE ratio of -0.77 and a beta of 0.49. Clene has a 52-week low of $0.25 and a 52-week high of $1.27.

Institutional Investors Weigh In On Clene

A number of hedge funds and other institutional investors have recently modified their holdings of CLNN. Cubist Systematic Strategies LLC purchased a new stake in shares of Clene during the second quarter worth about $29,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Clene in the first quarter worth approximately $29,000. Northern Trust Corp boosted its position in shares of Clene by 55.3% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock worth $49,000 after acquiring an additional 58,939 shares during the last quarter. UBS Group AG boosted its position in shares of Clene by 113.0% in the second quarter. UBS Group AG now owns 22,411 shares of the company’s stock worth $56,000 after acquiring an additional 11,887 shares during the last quarter. Finally, Csenge Advisory Group acquired a new stake in shares of Clene in the third quarter worth approximately $58,000. 3.87% of the stock is currently owned by hedge funds and other institutional investors.

Clene Company Profile

(Get Free Report)

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Featured Articles

Earnings History and Estimates for Clene (NASDAQ:CLNN)

Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.